Research ExplorerJournalsLANCET ONCOL Publications

LANCET ONCOL - The lancet oncology

51 - 68 out of 68Page size: 50

Publications

  1. 2013

  2. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

    Pivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., Scotto, N., Osborne, S., Fallowfield, L. & PrefHer Study Group, 01.09.2013, In: LANCET ONCOL. 14, 10, p. 962-70 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  3. Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial

    Westphal, M., Ylä-Herttuala, S., Martin, J., Warnke, P., Menei, P., Eckland, D., Kinley, J., Kay, R., Ram, Z. & ASPECT Study Group, 01.08.2013, In: LANCET ONCOL. 14, 9, p. 823-33 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  4. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)

    Pestalozzi, B. C., Holmes, E., de Azambuja, E., Metzger-Filho, O., Hogge, L., Scullion, M., Láng, I., Wardley, A., Lichinitser, M., Sanchez, R. I. L., Müller, V., Dodwell, D., Gelber, R. D., Piccart-Gebhart, M. J. & Cameron, D., 01.03.2013, In: LANCET ONCOL. 14, 3, p. 244-8 5 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  5. Towards individualised treatment in ovarian cancer

    Mahner, S. & Pfisterer, J., 01.02.2013, In: LANCET ONCOL. 14, 2, p. 101-2 2 p.

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

  6. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.

    Kuehn, T., Bauerfeind, I., Fehm, T., Fleige, B., Hausschild, M., Helms, G., Lebeau, A., Liedtke, C., von Minckwitz, G., Nekljudova, V., Schmatloch, S., Schrenk, P., Staebler, A. & Untch, M., 2013, In: LANCET ONCOL. 14, 7, p. 609-618 7.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  7. 2012

  8. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)

    Schmitz, N., Nickelsen, M., Ziepert, M., Haenel, M., Borchmann, P., Schmidt, C., Viardot, A., Bentz, M., Peter, N., Ehninger, G., Doelken, G., Ruebe, C., Truemper, L., Rosenwald, A., Pfreundschuh, M., Loeffler, M., Glass, B., German High-Grade Lymphoma Study Group (DSHNHL) & Bokemeyer, C., 01.12.2012, In: LANCET ONCOL. 13, 12, p. 1250-9 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  9. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.

    Bornhäuser, M., Kienast, J., Trenschel, R., Burchert, A., Hegenbart, U., Stadler, M., Baurmann, H., Schäfer-Eckart, K., Holler, E., Kröger, N., Schmid, C., Einsele, H., Kiehl, M. G., Hiddemann, W., Schwerdtfeger, R., Buchholz, S., Dreger, P., Neubauer, A., Berdel, W. E., Ehninger, G., Beelen, D. W., Schetelig, J. & Stelljes, M., 01.10.2012, In: LANCET ONCOL. 13, 10, p. 1035-1044 10 p., 10.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  10. CNS PNET molecular subgroups with distinct clinical features.

    von Bueren, A. & André, O., 2012, In: LANCET ONCOL. 13, 8, p. 753-754 8.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  11. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study.

    Biondi, A., Schrappe, M., Paola, D. L., Castor, A., Lucchini, G., Gandemer, V., Pieters, R., Stary, J., Escherich, G., Campbell, M., Li, C-K., Vora, A., Aricò, M., Röttgers, S., Saha, V. & Valsecchi, M. G., 2012, In: LANCET ONCOL. 13, 9, p. 936-945 9.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  12. Treatment of breast cancer during pregnancy: an observational study.

    Loibl, S., Han, S. N., von Minckwitz, G., Bontenbal, M., Ring, A., Giermek, J., Fehm, T., Kristel, V. C., Linn, S. C., Schlehe, B., Gziri, M. M., Westenend, P. J., Müller, V., Heyns, L., Rack, B., Ben, V. C., Harbeck, N., Lenhard, M., Halaska, M. J., Kaufmann, M., Nekljudova, V. & Amant, F., 2012, In: LANCET ONCOL. 13, 9, p. 887-896 9.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  13. 2009

  14. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study.

    Den, B., Monique, L., Slegtenhorst, V., Marjon, U., Menezes, D., Renée, X., Cheok, U., Meyling, H., Buijs-Gladdines, U., Jessica, G. C. A. M., Peters, U., Susan, T. C. J. M., Zutven, V., Laura, J. C. M., Beverloo, U., Berna, H., Spek, V. D., Peter, J., Escherich, G., Gaby, U., Horstmann, M., Martin, A., Janka-Schaub, G., Gritta, E., Kamps, U., Willem, A., Evans, U., William, E., Pieters, U. & Rob, U., 01.02.2009, In: LANCET ONCOL. 10, 2, p. 125-134 2.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  15. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.

    Finke, J., Bethge, W. A., Schmoor, C., Ottinger, H. D., Stelljes, M., Zander, A. R., Volin, L., Ruutu, T., Heim, D. A., Schwerdtfeger, R., Kolbe, K., Mayer, J., Maertens, J. A., Linkesch, W., Holler, E., Koza, V., Bornhäuser, M., Einsele, H., Kolb, H-J., Bertz, H., Egger, M., Grishina, O. & Socié, G., 2009, In: LANCET ONCOL. 10, 9, p. 855-864 9.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  16. Trials of prostate-cancer screening are not worthwhile.

    Dubben, H-H., 2009, In: LANCET ONCOL. 10, 3, p. 294-298 3.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  17. 2008

  18. Erythropoietins should be used according to guidelines.

    Aapro, M. S., Birgegård, G., Bokemeyer, C., Cornes, P., Foubert, J., Gascon, P., Glaspy, J., Hellström-Lindberg, E., Link, H., Ludwig, H., Osterborg, A., Repetto, L. & Soubeyran, P., 2008, In: LANCET ONCOL. 9, 5, p. 412-413 5.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  19. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

    Pfreundschuh, M., Schubert, J., Ziepert, M., Schmits, R., Mohren, M., Lengfelder, E., Reiser, M., Nickenig, C., Clemens, M., Peter, N., Bokemeyer, C., Eimermacher, H., Ho, A., Hoffmann, M., Mertelsmann, R., Trümper, L., Balleisen, L., Liersch, R., Metzner, B., Hartmann, F., Glass, B., Poeschel, V., Schmitz, N., Ruebe, C., Feller, A. C. & Loeffler, M., 2008, In: LANCET ONCOL. 9, 2, p. 105-116 2.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  20. 2007

  21. Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed?

    Bockhorn, M., Jain, R. K. & Munn, L. L., 01.05.2007, In: LANCET ONCOL. 8, 5, p. 444-448 5.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  22. 2005

  23. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.

    Berthold, F., Boos, J., Burdach, S., Erttmann, R., Henze, G., Hermann, J., Klingebiel, T., Kremens, B., Schilling, F. H., Schrappe, M., Simon, T. & Hero, B., 2005, In: LANCET ONCOL. 6, 9, p. 649-658 9.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  24. 2004

  25. Myeloid sarcoma of the prostate as first clinical manifestation of acute myeloid leukaemia.

    Spethmann, S., Heuer, R., Hopfer, H. & Tuinmann, G., 2004, In: LANCET ONCOL. 5, 1, p. 62-63 1.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Previous 1 2 Next